An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Researchers reported that adults with too much fat in their liver lost a lot of that fat while taking Wegovy over about a year and a half. In a group of 55 people who started with an average liver fat of 8.8%, the average fell to 3.1% after 72 weeks on the drug. The result is presented as a clear drop in liver fat percentage in this particular group. Wegovy is the brand name for the medicine semaglutide, a lab-made version of a hormone your gut makes after you eat. That hormone sends signals to your brain that help reduce appetite and slow how fast food leaves your stomach. Semaglutide is approved for weight loss and for treating type 2 diabetes at certain doses, and people usually get it as a once-weekly injection. What the study shows is a measured decrease in liver fat in these 55 adults over 72 weeks of treatment. The numbers reported—8.8% down to 3.1%—are averages for the group. The snippet doesn’t say whether there was a comparison group getting a placebo, how much weight participants lost overall, or whether other health measures changed. It also doesn’t describe how the liver fat was measured (for example, by MRI or blood tests) or whether the effect lasted after stopping the drug. This matters because having too much fat in the liver (nonalcoholic fatty liver disease, or NAFLD) can lead to inflammation, scarring, and, in some people, more serious liver damage. If a medicine commonly used for weight loss also reduces liver fat, it could help people lower their risk of liver-related problems and improve metabolic health. People with obesity, type 2 diabetes, or known fatty liver disease are the ones most likely to care about this kind of result. There are important caveats. The report covers 55 people, which is a modest sample size, and the snippet doesn’t give details on study design, side effects, or long-term outcomes. Semaglutide commonly causes nausea, constipation, and can increase the risk of gallbladder problems; rare but serious risks include pancreatitis. Wegovy is a prescription drug; it should be used under medical supervision and is not approved specifically for liver disease unless stated by regulators. We don’t know from this brief report whether the improvement in liver fat translates to better long-term liver health or whether results would be the same in larger, more diverse groups. Bottom line: In this small group, Wegovy was associated with a big average drop in liver fat over 72 weeks, which is promising, but we need fuller study details and longer follow-up before declaring it a cure for fatty liver.
Source: Stock Titan